AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30997542 — intervention group
Group type: COMPARATOR
Intervention: No chlorhexidine dressings
Number of subjects: 18286
Study 28252827 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises (Kegel exercises and pelvic movements) from 2 days postpartum until 3 months postpartum
Number of subjects: 189
Study 28252827 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Vagina Low Voltage Low Frequency Electric Stimulation (DES) 15 times (3 times a week for 30 min) starting at the sixth week postpartum combined with rehabilitation exercises
Number of subjects: 189
Study 28252827 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine postpartum guidance 2 hours postpartum
Number of subjects: 189
Study 28247679 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus Miramistin
Number of subjects: 150
Study 28247679 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 150
Study 24684985 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SD‐Ag)
Number of subjects: 18
Study 24684985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 18
Study 24684985 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 18
Study 24684985 — intervention group
Group type: EXPERIMENTAL
Intervention: SD‐Ag and mupirocin (combination)
Number of subjects: 18
Study 24684985 — intervention group
Group type: EXPERIMENTAL
Intervention: SD‐Ag, mupirocin, and clotrimazole (combination)
Number of subjects: 18
Study 24684985 — intervention group
Group type: EXPERIMENTAL
Intervention: SD‐Ag and mupirocin (combined effect)
Number of subjects: 18
Study 24684985 — intervention group
Group type: EXPERIMENTAL
Intervention: SD‐Ag, mupirocin, and clotrimazole (combined effect)
Number of subjects: 18
Study 23035004 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Number of subjects: 30
Study 21146205 — intervention group
Group type: EXPERIMENTAL
Intervention: VTD (Bortezomib with Thalidomide plus Dexamethasone)
Number of subjects: 480
Study 21146205 — intervention group
Group type: COMPARATOR
Intervention: TD (Thalidomide plus Dexamethasone)
Number of subjects: 480
Study 21146205 — intervention group
Group type: EXPERIMENTAL
Intervention: VTD
Number of subjects: 480
Study 21146205 — intervention group
Group type: COMPARATOR
Intervention: TD
Number of subjects: 480
Study 17533081 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary literature-based approach to treatment
Number of subjects: 0
Study 16322283 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy with Premarin
Number of subjects: 0
Study 16322283 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic estrogen sulfate conjugates
Number of subjects: 0
Study 16322283 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-dominated proliferative phase
Number of subjects: 0
Study 16322283 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial hyperplasia
Number of subjects: 0
Study 16322283 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 endometrioid adenocarcinoma
Number of subjects: 0
Study 16322283 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 endometrioid carcinoma
Number of subjects: 0
Study 16322283 — intervention group
Group type: COMPARATOR
Intervention: Normal endometrial epithelium
Number of subjects: 0
Study 16322283 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrioid tumors
Number of subjects: 0
Study 16322283 — intervention group
Group type: COMPARATOR
Intervention: Uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor
Number of subjects: 0
Study 12081832 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate-rich diet (400 microg folate/d)
Number of subjects: 126
Study 12081832 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplement (400 microg/d)
Number of subjects: 126
Study 12081832 — intervention group
Group type: COMPARATOR
Intervention: Exclusion diet (placebo daily)
Number of subjects: 126
Study 9459155 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (40 mg per day)
Number of subjects: 22
Study 9459155 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (40 mg of tamoxifen + 75 microg of CV 205-502 + 3 x 0.2 mg of octreotide)
Number of subjects: 22
Study 9459155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 22
Study 9459155 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 22
Study 7871564 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g of eicosapentanoic acid (EPA)
Number of subjects: 133
Study 7871564 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g of eicosapentanoic acid (EPA)
Number of subjects: 133
Study 7871564 — intervention group
Group type: COMPARATOR
Intervention: 9 g of corn oil (placebo)
Number of subjects: 133
Study 7871564 — intervention group
Group type: COMPARATOR
Intervention: 18 g of corn oil (placebo)
Number of subjects: 133
Study 7871564 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fish oil (EPA)
Number of subjects: 133
Study 7871564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fish oil (EPA)
Number of subjects: 133
Study 7871564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 133
Study 7871564 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (EPA and placebo)
Number of subjects: 133
Study 2371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow-up at 3 monthly intervals (follow-up group)
Number of subjects: 164
Study 2371432 — intervention group
Group type: COMPARATOR
Intervention: Annual follow-up (discharge group)
Number of subjects: 164
Study 7362785 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 7362785 — intervention group
Group type: COMPARATOR
Intervention: No anti-hypertensive treatment (Control)
Number of subjects: 0
Study 7362785 — intervention group
Group type: COMPARATOR
Intervention: Random sample from the same maternity hospital population
Number of subjects: 0
Study 31786286 — intervention group
Group type: EXPERIMENTAL
Intervention: David procedure
Number of subjects: 523
Study 31786286 — intervention group
Group type: COMPARATOR
Intervention: Bentall procedure
Number of subjects: 523
Study 30071753 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) documentation
Number of subjects: 98
Study 30071753 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a demographic variable
Number of subjects: 98
Study 27984005 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 1000
Study 27984005 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1000
Study 27984005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 1000
Study 25967270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 148
Study 25967270 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 148
Study 23984100 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% povidone iodine otic drops
Number of subjects: 34
Study 23984100 — intervention group
Group type: COMPARATOR
Intervention: 1% Clotrimazole and lignocaine drops
Number of subjects: 34
Study 17675766 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen
Number of subjects: 174
Study 17675766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 14988571 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy
Number of subjects: 834
Study 14988571 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (adjusted-dose warfarin)
Number of subjects: 834
Study 10776870 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair
Number of subjects: 176
Study 10776870 — intervention group
Group type: COMPARATOR
Intervention: Diversion
Number of subjects: 176
Study 8890138 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (first choice antibiotic for AOM)
Number of subjects: 0
Study 1583904 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral self-control training
Number of subjects: 140
Study 3161422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (20 micrograms/kg)
Number of subjects: 48
Study 3161422 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms/kg)
Number of subjects: 48
Study 3161422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (20 micrograms/kg) and Fentanyl (100 micrograms/kg)
Number of subjects: 48
Study 29799668 — intervention group
Group type: EXPERIMENTAL
Intervention: numeric with an icon array
Number of subjects: 648
Study 29799668 — intervention group
Group type: EXPERIMENTAL
Intervention: numeric with a set of 50 images
Number of subjects: 648
Study 29799668 — intervention group
Group type: EXPERIMENTAL
Intervention: numeric with a functional spinner
Number of subjects: 648
Study 29799668 — intervention group
Group type: COMPARATOR
Intervention: numeric only format
Number of subjects: 648
Study 25085651 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory attention
Number of subjects: 50
Study 25085651 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual attention
Number of subjects: 50
Study 25085651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both auditory and visual modalities
Number of subjects: 50
Study 25872500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sessions with a trained Physical Activity Facilitator delivering an intervention based on self‐determination theory
Number of subjects: 60
Study 25872500 — intervention group
Group type: COMPARATOR
Intervention: Booklet on healthy ageing
Number of subjects: 60
Study 24051419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (Gilenya)
Number of subjects: 712
Study 21888842 — intervention group
Group type: EXPERIMENTAL
Intervention: Zifko method of minimally invasive osteosynthesis with intramedullary K‐wire insertion (MIO group)
Number of subjects: 55
Study 21888842 — intervention group
Group type: COMPARATOR
Intervention: Open reduction with angle‐stable osteosynthesis using a Philos plate (ORIF group)
Number of subjects: 55
Study 19487582 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 59
Study 19487582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Number of subjects: 59
Study 19487582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 59
Study 19487582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 59
Study 19487582 — intervention group
Group type: COMPARATOR
Intervention: All 4 classes of drug
Number of subjects: 59
Study 19487582 — intervention group
Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 59
Study 17076365 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy
Number of subjects: 0
Study 17076365 — intervention group
Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 0
Study 19785223 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterinarians delivering education materials during routine dairy herd health visits
Number of subjects: 27
Study 19785223 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterinarians providing client lists for mailing education materials
Number of subjects: 27
Study 19785223 — intervention group
Group type: COMPARATOR
Intervention: Control group with veterinarians providing client lists but no education materials
Number of subjects: 27
Study 11759861 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery plus autogenous bone grafts alone (FG) (controls, n = 12)
Number of subjects: 25
Study 11759861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery plus non-resorbable barriers (FGM) (test 1, n = 20)
Number of subjects: 25
Study 11759861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery plus bioabsorbable barriers (FGRM) (test 2, n = 9)
Number of subjects: 25
Study 9380803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (2.5 mg/l of dialysis solution)
Number of subjects: 41
Study 9380803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (5 mg/l of dialysis solution)
Number of subjects: 41
Study 9380803 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline hydrochloride (0.5 mg/l of dialysis solution)
Number of subjects: 41
Study 9380803 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g% glucose dialysis solution
Number of subjects: 41
Study 7871062 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 20
Study 7871062 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg
Number of subjects: 20
Study 7871062 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 40 mg
Number of subjects: 20
Study 7871062 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 80 mg
Number of subjects: 20
Study 7871062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3530447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 115
Study 3530447 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 115
Study 30255400 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (AMIO) monotherapy (300 mg in 30 min + 1125 mg in 36 h iv)
Number of subjects: 812
Study 30255400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus Ranolazine (AMIO + RAN) combination (500 mg po + 375 mg after 6 h and 375 mg twice daily thereafter)
Number of subjects: 812
Study 30255400 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial diameter comparison
Number of subjects: 812
Study 27496105 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion (0.1 μg/kg/min for 24 hours)
Number of subjects: 340
Study 27496105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 27496105 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion
Number of subjects: 340
Study 24650009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (0.1, 0.3, or 0.5 mg/kg)
Number of subjects: 30
Study 24650009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 30
Study 24650009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22181973 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg letrozole/day for five days combined with intrauterine insemination
Number of subjects: 136
Study 22181973 — intervention group
Group type: COMPARATOR
Intervention: 100 mg clomiphene citrate/day for five days combined with intrauterine insemination
Number of subjects: 136
Study 19781127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (12-week teacher-implemented program with parent seminars)
Number of subjects: 191
Study 18853679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg orally 60 minutes before surgery) and ketamine (20 mg intravenous bolus followed by intraoperative perfusion of 20 mg h(‐1))
Number of subjects: 31
Study 18853679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 31
Study 18853679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and ketamine
Number of subjects: 31
Study 16135340 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms (DS)
Number of subjects: 400
Study 16135340 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse mental health functioning (MHF)
Number of subjects: 400
Study 16135340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant worsening (10 points) of DS and MHF
Number of subjects: 400
Study 16135340 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex, heroin as a problem substance, and race/ethnicity
Number of subjects: 400
Study 12566361 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated VEGF serum levels
Number of subjects: 1090
Study 12566361 — intervention group
Group type: EXPERIMENTAL
Intervention: High HGF levels
Number of subjects: 1090
Study 12566361 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF levels
Number of subjects: 1090
Study 10225081 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 40
Study 10225081 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 40
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg losigamone
Number of subjects: 52
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg losigamone
Number of subjects: 52
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg losigamone
Number of subjects: 52
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg losigamone for 6 days (t.i.d.)
Number of subjects: 52
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg losigamone for 28 days
Number of subjects: 52
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg losigamone for 28 days
Number of subjects: 52
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 mg losigamone for 28 days
Number of subjects: 52
Study 8688997 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and antipyrine kinetics
Number of subjects: 52
Study 2070860 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicles yielding successfully fertilized and cleaved ova
Number of subjects: 55
Study 2070860 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicles with mature oocyte‐corona‐cumulus complexes and unfertilized oocytes
Number of subjects: 55
Study 6129370 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF-40 (1 microgram/kg bodyweight, administered as an intravenous bolus)
Number of subjects: 6
Study 6129370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6129370 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF-40
Number of subjects: 6
Study 30908853 — intervention group
Group type: EXPERIMENTAL
Intervention: FHSQ pain subscale
Number of subjects: 88
Study 30908853 — intervention group
Group type: EXPERIMENTAL
Intervention: FFI‐RS pain subscale
Number of subjects: 88
Study 30908853 — intervention group
Group type: EXPERIMENTAL
Intervention: 100‐mm VAS of pain severity while walking
Number of subjects: 88
Study 30786861 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity exercise program (Borg perceived rating scale 13-14), at least three times weekly; one supervised group training and two home-based sessions.
Number of subjects: 724
Study 30786861 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care (control group).
Number of subjects: 724
Study 29042662 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα-2b
Number of subjects: 98
Study 29042662 — intervention group
Group type: COMPARATOR
Intervention: Continuing NA therapy
Number of subjects: 98
Study 27054324 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting physical activity guidelines of 150 moderate and vigorous minutes per week (≥ 600 MET adjusted minutes)
Number of subjects: 3414
Study 27054324 — intervention group
Group type: EXPERIMENTAL
Intervention: Total minutes per week of moderate and vigorous/strenuous activity greater than 743 MET adjusted minutes
Number of subjects: 3414
Study 27054324 — intervention group
Group type: COMPARATOR
Intervention: Participants who did not meet US physical activity guidelines
Number of subjects: 3414
Study 25099775 — intervention group
Group type: EXPERIMENTAL
Intervention: RehaCom cognitive training
Number of subjects: 240
Study 25099775 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 240
Study 25099775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RehaCom cognitive training and acupuncture
Number of subjects: 240
Study 25099775 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 240
Study 22824097 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS‐steered treatment (DAS ≤ 2.4)
Number of subjects: 275
Study 19615091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (target carbohydrate content: <40% energy)
Number of subjects: 200
Study 19615091 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (target carbohydrate content: >55% energy)
Number of subjects: 200
Study 17916060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0
Study 17916060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir postexposure prophylaxis
Number of subjects: 0
Study 15073704 — intervention group
Group type: COMPARATOR
Intervention: Nitric oxide (NO)
Number of subjects: 90
Study 15073704 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of milrinone
Number of subjects: 90
Study 15073704 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of milrinone and NO
Number of subjects: 90
Study 11835382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (8g/m2)
Number of subjects: 37
Study 9509951 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar pregnancy
Number of subjects: 20
Study 9509951 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 20
Study 7997415 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/kg/day reducing to zero over 14 days (n = 12)
Number of subjects: 21
Study 7997415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 21
Study 2834942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet for 8 weeks
Number of subjects: 0
Study 2834942 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber diet for 8 weeks
Number of subjects: 0
Study 31239112 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/DRSP
Number of subjects: 120
Study 31239112 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA
Number of subjects: 120
Study 27651218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg daily
Number of subjects: 20
Study 27651218 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1.5 g daily
Number of subjects: 20
Study 25179468 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched bread and drinking yoghurt
Number of subjects: 47
Study 25179468 — intervention group
Group type: COMPARATOR
Intervention: Normal, non-enriched products
Number of subjects: 47
Study 23273855 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual-print decision aid
Number of subjects: 255
Study 23273855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 255